Aeirtec have a clinical pharmacology/pharmacology background and within 2 decades of experience in running clinical trials, they have 2 decades of blood marker data provision in efficacy, drug candidate mechanism of action, translation and exploratory marker changes in clinical studies (phase II and III). Aeirtec have patented technology for unique high sensitivity clinical study blood marker immunoassay (1, 2) and so provide the highest sensitivity immunoassay in studies requiring simultaneous measurement of multiple clinal markers (eg greater than 10 marker multiplexing). The marker multiplexing enables economies in cost and a magnitude greater data acquisition from clinical samples. Aeirtec have establish a 20 marker panel for monitoring COVID-19-induced ARDS markers that has revealed clinical efficacy against the ARDS immune /inflammatory profile (3) Aeirtec advises on marker panel choice within the therapeutic context and this is supported by post study provision of in depth multivariate statistical analysis for demonstration of candidate efficacy and mechanism of action (eg 4). Aeirtec is located in the UK, working under compliance with the principles of GLP and ISO17025 and their broad clinical study expertise has evolved from clinical study engagement with both biotech and pharma (Aeirtec client examples: AstraZeneca, Altana, Athersys, Bayer, Boehringer Ingelheim, Cara Therapeutics, GlaxoSmithKline, Novartis, Pfizer, UCB) (1) Patent issued: Immobilised bead immunomultiplex assay US2013157288A1 (B2) https://patents.google.com/patent/US20130157288A1/en22 (2) Patent pending: Assay analysis WO2020120996 (A1) https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020120996 (3) http://www.aeirtec.com/cytokine-storm/4595038618 (4) https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30046-7/fulltext
